

**UNITED STATES JUDICIAL PANEL  
on  
MULTIDISTRICT LITIGATION**

**IN RE: VALSARTAN, LOSARTAN, AND IRBESARTAN  
PRODUCTS LIABILITY LITIGATION**

MDL No. 2875

**TRANSFER ORDER**

**Before the Panel:** Plaintiff in the action listed on Schedule A (*Hall*) moves under Panel Rule 7.1 to vacate the order conditionally transferring the action to MDL No. 2875. Defendant Torrent Pharma, Inc., opposes the motion and supports transfer.

After considering the argument of counsel, we find that this action involves common questions of fact with the actions transferred to MDL No. 2875, and that transfer under 28 U.S.C. § 1407 will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. The actions in MDL No. 2875 involve common factual questions arising from allegations that generic formulations of valsartan, losartan, and irbesartan contain nitrosamine impurities<sup>1</sup> and that the nitrosamines present a risk of cancer and other injuries. *See In re Valsartan Prods. Liab. Litig.*, 433 F. Supp. 3d 1349, 1352-53 (J.P.M.L. 2019). The *Hall* action undisputedly involves the same factual issues.

In support of the motion to vacate, plaintiff principally argues that her action was improperly removed and that the interest of efficiency is best served by allowing the transferor court to rule on the jurisdictional objections raised in her motion for remand to state court. The Panel has held that such jurisdictional objections generally do not present an impediment to transfer. *See, e.g., In re Darvocet, Darvon and Propoxyphene Prods. Liab. Litig.*, 939 F. Supp. 2d 1376, 1377 (J.P.M.L. 2013) (“We have often held . . . that jurisdictional issues, such as a claimed lack of diversity or absence of a federal question, do not present an impediment to transfer, as plaintiffs can present such arguments to the transferee judge”).

Plaintiff also argues that transfer will be inconvenient and impose an undue hardship. In deciding transfer, the Panel “look[s] to the overall convenience of the parties and witnesses, not just those of a single plaintiff or defendant in isolation.” *See In re Watson Fentanyl Patch Prods. Liab. Litig.*, 883 F. Supp. 2d 1350, 1351-52 (J.P.M.L. 2012). Here, the overall interests of convenience and efficiency will be served by transferring *Hall*, as the action shares significant

---

<sup>1</sup> The nitrosamines at issue include N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA).

factual questions with the actions in the MDL, and likely will benefit from common pretrial proceedings and the transferee judge's expertise on the issues.

IT IS THEREFORE ORDERED that the action listed on Schedule A is transferred to the District of New Jersey and, with the consent of that court, assigned to the Honorable Robert B. Kugler for inclusion in the coordinated or consolidated pretrial proceedings.

PANEL ON MULTIDISTRICT LITIGATION

A handwritten signature in cursive script, reading "Karen K. Caldwell", is positioned above a horizontal line.

Karen K. Caldwell

Chair

Nathaniel M. Gorton  
David C. Norton  
Dale A. Kimball

Matthew F. Kennelly  
Roger T. Benitez  
Madeline Cox Arleo

**IN RE: VALSARTAN, LOSARTAN, AND IRBESARTAN  
PRODUCTS LIABILITY LITIGATION**

MDL No. 2875

**SCHEDULE A**

Southern District of Alabama

HALL v. TORRENT PHARMA, INC., ET AL., C.A. No. 2:21-00357